Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Apogee Therapeutics's APG-777?
APG-777 is a monoclonal antibody commercialized by Apogee Therapeutics, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema)....
Data Insights
APG-777 by Apogee Therapeutics for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
APG-777 is under clinical development by Apogee Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to...